Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sanofi’s Nov.20 event important for MannKind investors
RBC Capital Markets analysts Adnan Butt and John Chung said in a research note that Sanofi will hold an analyst event on Nov.20. At the event, the French company is expected to highlight its plans, commitment, commercialization outlook and preparations for Afrezza. Analysts said the debate around Afrezza’s market potential and MannKind’s profitability will continue at least until Q1, 2015. While MannKind will be manufacturing Afrezza, Sanofi will be responsible for commercialization, development and regulatory activities. MannKind has started commercial production of its inhaled insulin treatment. The company is also increasing capacity of its Danbury facility by adding two more production lines. RBC Capital Markets has an Outperform rating on MannKind with $13 price objective.
You have a lot of short interest out there that seems to cling to this company and no news that I can think of in the short term will only add to the bet down.jmo long mnkd.
Missed this from the pr
"(1 )Under the collaboration and license agreement, Sanofi will be responsible for global commercial, regulatory and development activities. (2)Under a separate supply agreement, MannKind will manufacture Afrezza at its manufacturing facility in Danbury, Connecticut. In addition, the companies are planning to collaborate to expand manufacturing capacity to meet global demand as necessary.
Agree lars
This story is germane to Afrezza in two ways. One, because MannKind has tried to solve some of the same problems that affected Nektar's product. And two, because MannKind has failed to realize the main problem vexing this budding market.
One of the problems that Afrezza has solved is size. Exubera was intimidating. Try flipping out a foot-size cylinder from your pocket during a dinner date and your date's surprised face will tell you how discreet that is. Afrezza, on the other hand, is small and cool. It fits right into your palm, so you can use it without drawing attention in a public place. Or frightening your date at restaurants.
The other problem was the drug delivery itself. Exubera's dosing was confusing, given a non-linear change versus comparable amounts of insulin. Compared to an injection syringe where you can precisely regulate quantity, Exubera's dosing could be more hit-or-miss for patients. Afrezza, now, is much more carefully developed using its proprietary Technosphere technology
Aree lars
From October 21st:
Fortunately, the lack of confidence isn't particularly worrisome for MannKind. As part of its recently signed deal with Sanofi to market Afrezza, MannKind received $150 million up front, and Sanofi is loaning MannKind up to another $175 million to cover the losses from their partnership until Afrezza is profitable.
MannKind shouldn't need to raise capital in the near future, so the share price in the short term isn't a concern. (And even if it did need to raise capital, billionaire namesake and CEO Alfred Mann can continue to help foot the bill.) If Sanofi and MannKind can prove that doctors are willing to adopt inhaled insulin, investors will come back and MannKind's share price will go up substantially. And that would make everyone dance.
Could be a tipping point we shall see in a couple of days.Thanks TREND1 not a chart guy but still learning. have a good day.
bob so your going to buy gas with gold and silver. good luck with that.
I hope they got some balls and the numbers go up.but sure think they are smarter than that. GLTY TREND1 And thanks for the info.
Some big numbers for such a small float.JMO
Let em roll a seven moxa.i'm in the same boat as you.GLTU
No hope wsj IMO.
bobhwang there is no hope with this one.GLTY
help me sounds like your mad about something.just remember that song don't worry be happy everything will be just fine.
Let her blow I caught a bottom and a top once in my life. And now im going to try to do it here. By pure luck of course. That was in 1999 or 2000. 2$-25$ the name of that company was JB Oxford don't think they exist anymore FWIW. glta
tyfoidhana that will work for me. GLTU
help me I think you got that confused your thinking of John A Wells.chair of the wells notice.
Big jump here:
MannKind Corp. (NASDAQ: MNKD) saw its short interest rise to 78.58 million, with 14.5 days to cover, against the previous 74.29 million shares short. The current level is the highest short interest reading for the past 52 weeks. Investors appear bearish on this stock and have latched on to its most recent slide from its 52-week high in June. The company’s stock closed Thursday at $4.97, and it has a 52-week trading range of $3.80 to $11.48.
Jjackas how can you make a statement like that when the drug will hit the market in Q1 of 2015 and that's not far off.
help me it's over been over for a long time.
So glad I won't have to sell my hat and poker chip.Are these people for real?
My thoughts are with you gotta buy more.
I like your attitude D. GLTU
He may need a pacer in his line of work.
stuffed that's hilarious. Maybe he used that hot dog guy his name escapes me at the moment because I know them hot dogs are not meant for human consumption.
Yeah you might be right that might have been a sleigh instead of a golf cart the whole bunch was there that night Topo and the whole crew. What an idiot I was!
What became of his brother Ron I remember him picking us up at the gate in his golf cart and driving us to the tent at one of the races in Chicago.
Can MannKind hook up with other drug producers or is this a one shot deal?
If we go much lower my gut say's buy more.GLTA
Where do your charts see us landing.TIA
Neverending I hopes he makes a trillion dollars on every deal.Ijust don't like him.jmo
Met him at SHM in Chicago no good ep.
I like that Leckrone is a junk yard dog.
From what I can see Ms. Shell has not been wrong since I have been following her. Good luck to you.
DWP maybe your right or maybe your wrong but if we knew what the markets would bring ahead of time we would all be happy.GLTY
Who want's to buy a cmkx hat and a poker chip?
I missed this one, nice article.
Afrezza Is To Apple Macintosh What Exubera Was To The IBM PC.
Perhaps it's too late in life for Alfred Mann to be considered the Steve Jobs of diabetes. And perhaps the metaphor itself is difficult for some to condone. But the fact is that some inventions are culturally disruptive in that they change the way we live, work and play. They literally change the way we perceive ourselves to be as human beings and change the way we interact with each other.
In his final technology products column for the Wall Street Journal - and I never read one of them, Walt Mossberg compiled a list of the 12 most influential devices he had reviewed over the previous 2 decades of his then concluding career. On that list, you'll find 3 Apple icons - the iPod, iPhone and iPad. But the 2 Steves - Wozniak and Jobs got started sooner in life creating disruptive technologies than Mr. Mossberg's career of coverage allowed for.
Like the diabetes market, the world of personal computing was already established before Apple (AAPL) made the concept popular. Shadow casting monoliths like Xerox and IBM were in full control along with startups like Atari and Commodore.
In 1981, IBM was poised to dominate the landscape with the IBM PC that imitated most of Apple's disruptive features embodied in the Apple II. But Steve Jobs by this time was maniacally possessed with the idea of making a machine that was easier to operate, less obtrusive and more user friendly. Does that description remind you at all of the qualities Afrezza offers? It should. Because I believe these technologies are remarkably analogous one to another.
I hope we move up a bit today.Feels like it to me.GLTA
I wish i had the markets figured out like you i would be rich. glty.
Slowly but surely. Saborte79 glty.
F-15 why not send your thoughts or ideas to the company.you do own shares and that is your right.glty